Blueprint Medicines Corporation focuses on Ayvakit, BLU-808, and Elenestinib with strong potential in mast cell disorders.

Blueprint Medicines' strong pipeline and Ayvakit growth make it promising. Read why BPMC stock is rated "Hold" due to high ...

which is already approved by the United States Food and Drug Administration to treat gastrointestinal stromal tumors with a PDGFRA exon 18 mutation as well advanced systemic mastocytosis and ...

Because of the often nonspecific nature of MCL, diagnostic efforts need to be better streamlined to reduce the risk of misdiagnosis.

Healthcare Analysts provide expert insights on current and emerging treatments for Systemic Mastocytosis (relevant companies Blueprint ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Blueprint Medicines Corporation (NASDAQ:BPMC) ...

Avapritnib has been approved to treat advanced systemic mastocytosis and indolent systemic mastocytosis and gastrointestinal stromal tumors with a platelet-derived growth factor receptor alpha (PDGFRA ...

Schroder Investment Management Group lowered its stake in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 60.1% in the ...

CAMBRIDGE, Mass., March 31, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC ) today announced that company management will participate virtually in a fireside chat at the 24 th ...

Shares of Cogent Biosciences, Inc. (NASDAQ:COGT – Get Free Report) have received an average rating of “Moderate Buy” from the ...

Duke University blood cancer specialist Lindsay Rein, MD, has developed a rare expertise in myeloproliferative neoplasms ...